We are pleased to announce that James Rickard has been appointed as the new Chief Scientific Officer of the Richmond Research Institute.

James Rickard is a Research Pharmacist and has been involved in translational research to deliver new therapeutic options to patients throughout his career. Driven by his desire for better outcomes for patients, he spent his early career working across several London Teaching Hospitals in Clinical Pharmacy, Drug Manufacture and Clinical Trials, culminating in taking up the role of Deputy Chief Pharmacist for Barts Health NHS Trust.

He opted for a change of industry in 2018 to lead the pre-clinical and clinical drug development programmes for the first recognised Point of Care Manufactured product in the UK.

He is a Senior Visiting Lecturer at Kings College London in the Institute of Pharmaceutics Science supporting MSc and PhD research projects. He is also a member of the British Pharmacopoeia Commission, and acts as department advisor for the Medicinal Chemistry 2 Expert Advisory Group.

James Rickard, Chief Scientific Officer:

‘I’m excited to join Richmond Research Institute, a Non-Commercial Research Sponsor office as Chief Scientific Officer to lead the institute.

‘Created with the aim of delivering research of quality and speed to provide impactful improvements to patient safety and clinical outcomes. This role gives me the opportunity to draw on my healthcare, industry and academia experience in collaboration with the industry leading staff knowledge within Richmond Research Institute, to aid accelerating ambitious research programmes, and ultimately to benefit patient’s lives.’

As the Chief Scientific Officer at the Richmond Research Institute (RRI), James brings vast experience of healthcare, industry and academic research alongside a passion for improving patients’ lives. The RRI was established to deliver impactful research at pace and has access to state-of-the-art expertise & facilities of Richmond Pharmacology, bringing together the best elements of healthcare and industry to deliver benefits to patients sooner.

Latest news

Single-dose gene silencing cure for fatal heart disease comes one step closer

March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read more

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more


ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event